|Articles|January 11, 2022

In Turbulent Times, Taking Care of One’s Self

During a continuation of a difficult time in our history, overwhelmed providers need to take a step back and find time for themselves to unwind and destress from COVID-19.


The burden of the Omicron variant has been very difficult on everyone. The prevalence of it becoming abundant in our greater society is apparent, especially as cases go up and more people need care.

There are ongoing reports that some hospitals and medical centers are being inundated by COVID-19. Facilities are seeing larger numbers of cases and hospital personnel are contracting the more contagious variant of COVID-19, thus in some cases, leaving staff short-handed and exacerbating the problem which can lead to burnout.

Some providers and caregivers are choosing to leave the medical industry altogether due to this never-ending pandemic. Although no one knows when the pandemic will transition into an endemic, if you take a historical perspective, this virus will eventually evolve to that stage.

In the meantime, providers and caregivers need to try to find a way to balance their work lives with time for themselves.

Ami Multani, MD, medical director of infectious disease, Fenway Health has been thinking about the historical context of the pandemic in the early days of it in 2020 and how we can manage through the continuation of difficult times. She offers some insights into looking at COVID-19 and how it parallels with the early days of the AIDs crisis. She also discusses strategies to help fellow providers to decompress and feel better about the current state of things and the future.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.